5 Things You Need to Know From AbbVie's Q2 Earnings Results

AbbVie (NYSE: ABBV) needed some good news: Its announcement late last month of a plan to acquire Allergan went over like a lead balloon on Wall Street, and its stock price is down 25% so far this year. Investors continue to worry about the slumping sales of the big pharma company's top-selling drug Humira.